Biopharmaceutical firm Immunomedics has added another U.S. patent to its intellectual property portfolio.
The allowed claims under U.S. Patent No. 8,168,186 cover methods of use of bispecific antibodies for pretargeted imaging and therapy of diseases, such as cancer, autoimmune disease, septic shock, and infectious disease, according to Immunomedics. The patent provides coverage until February 2021.
